Imunon Inc (nasdaq:IMNN) Share Price

Company Profile

Business description
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
Contact
997 Lenox Drive
Suite 100
LawrencevilleNJ08648
USA
T: +1 609 896-9100
E: [email protected]
https://www.imunon.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
20

Recommended

Sales growth but lack of margin expansion due to competition.

Johannes Faul, CFA | 15 June 2026

Discounted Aussie shares that offer a tax rebate.

Tyger Fitzpatrick | 14 June 2026

Pre-IPO holders could start selling later this summer, and earnings will be an important test.

Tom Lauricella | 14 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,128.00	14.60	0.16%
CAC 40	8,456.38	105.51	1.26%
DAX 40	25,014.86	379.56	1.54%
Dow JONES (US)	51,202.26	353.51	0.70%
FTSE 100	10,520.23	48.51	0.46%
HKSE	24,831.00	112.90	0.46%
NASDAQ	25,888.84	79.18	0.31%
Nikkei 225	69,317.50	3,297.46	4.99%
NZX 50 Index	13,360.59	33.28	-0.25%
S&P 500	7,431.46	37.16	0.50%
S&P/ASX 200	8,914.00	7.00	0.08%
SSE Composite Index	4,096.47	64.96	1.61%